Immunological investigations · 2025
Immunotherapy Strategies for Systemic Lupus Erythematosus: Focusing on CAR-T Cell Therapy.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tu Miao, Liu Wan, Wei Yujiao, Cao Kunyu, Du Xiaoping, Ju Jiyu
Аннотация
INTRODUCTION: Systemic Lupus Erythematosus (SLE) is an incurable autoimmune disease. The remarkable success of Chimeric Antigen Receptor T-cell (CAR-T) therapy in oncology has prompted its investigation for autoimmune conditions, particularly SLE.
METHODS: This review synthesizes current evidence, primarily from the last five years, to elucidate the pathological basis, mechanisms, advancements, and future directions of CAR-T therapy for SLE.
RESULTS: Evidence indicates that CAR-T therapy, which targets pathogenic B cells or restores immune tolerance, is a promising intervention for SLE. Preclinical and early clinical data suggest it can effectively mitigate symptoms and may induce sustained, drug-free remission, representing a shift from chronic management.
DISCUSSION: CAR-T cell therapy represents a transformative potential for SLE treatment. Future efforts should focus on target optimization, safety enhancement, and validation of long-term efficacy in larger clinical trials.
METHODS: This review synthesizes current evidence, primarily from the last five years, to elucidate the pathological basis, mechanisms, advancements, and future directions of CAR-T therapy for SLE.
RESULTS: Evidence indicates that CAR-T therapy, which targets pathogenic B cells or restores immune tolerance, is a promising intervention for SLE. Preclinical and early clinical data suggest it can effectively mitigate symptoms and may induce sustained, drug-free remission, representing a shift from chronic management.
DISCUSSION: CAR-T cell therapy represents a transformative potential for SLE treatment. Future efforts should focus on target optimization, safety enhancement, and validation of long-term efficacy in larger clinical trials.